Evidence map›Paper›PMID 34864989›Full record

ArticleEndocrinology2022

Downregulation of Dihydrotestosterone and Estradiol Levels by HEXIM1.

Fitya Mozar, Vikas Sharma, Shashank Gorityala, Jeffrey M Albert, Yan Xu, Monica M Montano

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Fitya MozarDepartment of Pharmacology; Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
Vikas SharmaDepartment of Pharmacology; Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
Shashank GorityalaDepartment of Chemistry, Cleveland State University, Cleveland, OH 44115, USA.
Jeffrey M AlbertDepartment of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
Yan XuDepartment of Chemistry, Cleveland State University, Cleveland, OH 44115, USA.
Monica M MontanoDepartment of Pharmacology; Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.ORCID 0000-0002-6948-7676
University School · USCleveland State University · USCase Western Reserve University · US

Funding

HEXIM1 regulation of transcriptional networks critical for tumor suppressionR01CA195558 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MONTANO, MONICA · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA195558
6 · The paper itself

Abstract

We have previously reported that hexamethylene bis-acetamide inducible protein 1 (HEXIM1) inhibits the activity of ligand-bound estrogen receptor α (ERα) and the androgen receptor (AR) by disrupting the interaction between these receptors and positive transcriptional elongation factor b (P-TEFb) and attenuating RNA polymerase II (RNAPII) phosphorylation at serine 2. Functional consequences of the inhibition of transcriptional activity of ERα and AR by HEXIM1 include the inhibition of ERα- and AR-dependent gene expression, respectively, and the resulting attenuation of breast cancer (BCa) and prostate cancer (PCa) cell proliferation and growth. In our present study, we determined that HEXIM1 inhibited AKR1C3 expression in BCa and PCa cells. AKR1C3, also known as 17β-hydroxysteroid dehydrogenase (17β-HSD) type 5, is a key enzyme involved in the synthesis of 17β-estradiol (E2) and 5-dihydrotestosterone (DHT). Downregulation of AKR1C3 by HEXIM1 influenced E2 and DHT production, estrogen- and androgen-dependent gene expression, and cell proliferation. Our studies indicate that HEXIM1 has the unique ability to inhibit both the transcriptional activity of the ER and AR and the synthesis of the endogenous ligands of these receptors.

Indexed as

Down-RegulationGene Expression RegulationBreast NeoplasmsCell Line, TumorCell ProliferationDihydrotestosteroneEstradiolEstrogen Receptor alphaEstrogensFemaleHumansLigandsMaleMCF-7 CellsProstatic NeoplasmsReceptors, AndrogenDihydrotestosteroneESR1 protein, humanEstradiolEstrogen Receptor alphaEstrogensHEXIM1 protein, humanLigandsReceptors, AndrogenRNA-Binding ProteinsRNA, Small InterferingTranscription FactorsAKR1C3breast cancerHEXIM1prostate cancer

Identifiers

PMID34864989
PMCPMC8645165
OpenAlexW4200380173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.